The 2018 Amyloid, Tau and Neurodegeneration (ATN) research framework for Alzheimer’s disease (Ad) provides a systematic method to determine AD continuum designation.1 In this framework, extracellular amyloid beta (Aβ) plaques and intracellular hyperphosphorylated tau neurofibrillary tangles are the two most important pathological hallmarks, which precede neurodegeneration. Here, MAPT is linked to Alzheimer disease.